1
|
Cazzolla A, Mondala JRM, Wanigasekara J, Carroll J, Daly N, Tiwari B, Casey A, Curtin JF. Synthesis of cationic liposome nanoparticles using a thin film dispersed hydration and extrusion method. PLoS One 2024; 19:e0300467. [PMID: 38593146 PMCID: PMC11003666 DOI: 10.1371/journal.pone.0300467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 02/03/2024] [Indexed: 04/11/2024] Open
Abstract
Liposome nanoparticles can carry a wide range of therapeutic molecules including small molecules and nucleic acid-based therapeutics. Potential benefits include translocation across physiological barriers, reduced systemic toxicity, and enhanced pharmacokinetic parameters such as absorption, distribution, selective release and optimal elimination kinetics. Liposome nanoparticles can be generated with a wide range of natural and synthetic lipid-based molecules that confer desirable properties depending on the desired therapeutic application Nel et al (2023), Large (2021), Elkhoury (2020). This protocol article seeks to detail the procedures involved in the production of cationic liposomes using thin-film dispersed hydration method with an estimated uniform size of 60-70 nm for targeted drug administration in tumor cells, by modifying the previous one also published by the same authors cited here. The method was carrying out using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl (DOTAP, 2 mg) as cationic lipid and cholesterol (0.5 mg) in a molar ratio of 7:3 respectively. The liposomal suspension was obtained and its physical, chemical and biological properties were determined. A two-step extrusion process, using 100 nm and 50 nm polycarbonate membranes, was carried. The results demonstrate generation of liposome nanoparticles with a size of 60-70 nm stable for at least 16 weeks and with an encapsulation efficiency of approximately 81% using Doxorubicin.
Collapse
Affiliation(s)
- Alessandro Cazzolla
- School of Food Science and Environmental Health, Technological University Dublin, Dublin, Ireland
- Environmental Sustainability & Health Institute (ESHI), Greenway Hub, Technological University Dublin, Dublin, Ireland
- FOCAS Research Institute, Technological University Dublin, Dublin, Ireland
| | - Julie Rose Mae Mondala
- School of Food Science and Environmental Health, Technological University Dublin, Dublin, Ireland
- Environmental Sustainability & Health Institute (ESHI), Greenway Hub, Technological University Dublin, Dublin, Ireland
- FOCAS Research Institute, Technological University Dublin, Dublin, Ireland
| | - Janith Wanigasekara
- School of Food Science and Environmental Health, Technological University Dublin, Dublin, Ireland
- Environmental Sustainability & Health Institute (ESHI), Greenway Hub, Technological University Dublin, Dublin, Ireland
- FOCAS Research Institute, Technological University Dublin, Dublin, Ireland
- Department of Food Biosciences, Teagasc Food Research Centre, Ashtown, Dublin, Ireland
| | - Joanna Carroll
- School of Food Science and Environmental Health, Technological University Dublin, Dublin, Ireland
| | - Noah Daly
- School of Food Science and Environmental Health, Technological University Dublin, Dublin, Ireland
| | - Brijesh Tiwari
- Department of Food Biosciences, Teagasc Food Research Centre, Ashtown, Dublin, Ireland
| | - Alan Casey
- School of Physics, Clinical and Optometric Sciences, Technological University Dublin, Dublin, Ireland
| | - James F. Curtin
- Environmental Sustainability & Health Institute (ESHI), Greenway Hub, Technological University Dublin, Dublin, Ireland
- FOCAS Research Institute, Technological University Dublin, Dublin, Ireland
- Faculty of Engineering & Built Environment, Technological University Dublin, Dublin, Ireland
| |
Collapse
|
2
|
Abstract
Therapeutic agents that inhibit a single target often cannot combat a multifactorial disease such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications such as the development of resistance. There are two predominant types of MTIs, (a) single drug inhibitor (SDIs) that affect multiple pathways simultaneously, and (b) combinatorial agents or multi-drug inhibitors (MDIs) that inhibit multiple pathways. Single agent multi-target kinase inhibitors are amongst the most prominent class of compounds belonging to the former, whereas the latter includes many different classes of combinatorial agents that have been used to achieve synergistic efficacy against cancer. Safe delivery and accumulation at the tumor site is of paramount importance for MTIs because inhibition of multiple key signaling pathways has the potential to lead to systemic toxicity. For this reason, the development of drug delivery mechanisms using nanotechnology is preferable in order to ensure that the MDIs accumulate in the tumor vasculature, thereby increasing efficacy and minimizing off-target and systemic side effects. This review will discuss how nanotechnology can be used for the development of MTIs for cancer therapy and also it concludes with a discussion of the future of nanoparticle-based MTIs as well as the continuing obstacles being faced during the development of these unique agents.’
Collapse
Affiliation(s)
- Raghavendra Gowda
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Penn State Hershey Melanoma Center, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Penn State Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; The Foreman Foundation for Melanoma Research, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | - Nathan R Jones
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | - Shubhadeep Banerjee
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Penn State Hershey Melanoma Center, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Penn State Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | - Gavin P Robertson
- Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Department of Pathology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Department of Dermatology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Department of Surgery, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Penn State Hershey Melanoma Center, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; Penn State Melanoma Therapeutics Program, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA ; The Foreman Foundation for Melanoma Research, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| |
Collapse
|